Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway
Oslo, Norway, 12 January 2022 – Targovax ASA (OSE: TRVX) a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that Innovation Norway has awarded Targovax an NOK 8.2m grant to accelerate product development activities related to the company’s TG mutant RAS vaccine program and planned clinical trials.Awarded by: Innovation NorwayGranted amount: NOK 8.2mTime frame: 2022-2024 Kristin Willoch Haugen, Director of Innovation Norway Oslo Viken, commented: “Through this project Targovax and their partners aim to solve an